Teva Pharmaceuticals
TEVA
773 hedge funds and large institutions have $27B invested in Teva Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 60 funds opening new positions, 254 increasing their positions, 309 reducing their positions, and 65 closing their positions.
126% more call options, than puts
Call options by funds: $1.35B | Put options by funds: $597M
4% more capital invested
Capital invested by funds: $26B → $27B (+$933M)
0.48% more ownership
Funds ownership: 52.26% → 52.74% (+0.48%)
1% less funds holding
Funds holding: 780 → 773 (-7)
8% less first-time investments, than exits
New positions opened: 60 | Existing positions closed: 65
4% less funds holding in top 10
Funds holding in top 10: 49 → 47 (-2)
18% less repeat investments, than reductions
Existing positions increased: 254 | Existing positions reduced: 309
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$376M |
| 2 |
Boston Partners
Boston,
Massachusetts
|
+$259M |
| 3 |
William Blair & Company
Chicago,
Illinois
|
+$246M |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$143M |
| 5 |
SCM
Scopia Capital Management
New York
|
+$141M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
-$500M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$164M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$148M |
| 4 |
Bank of New York Mellon
New York
|
-$132M |
| 5 |
PC
PointState Capital
New York
|
-$110M |
TEVA Hedge Fund Activity: Q3 2014 in Review
773 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q3 2014, worth a combined $27B — up 3.6% from $26B a quarter earlier.
Sellers outnumbered buyers: 65 funds closed out of TEVA and 60 opened new positions — a net loss of 5 holders — while 309 trimmed existing stakes and 254 added.
The largest buyer was Waddell & Reed Financial, adding an estimated $376M. The largest seller was Norges Bank, cutting an estimated $500M.
- 773 institutional investors held Teva Pharmaceuticals (TEVA) as of Q3 2014, down from 780 in Q2 2014.
- Funds reported $27B of Teva Pharmaceuticals stock for Q3 2014, up 3.6% quarter-over-quarter.
- 60 funds opened new Teva Pharmaceuticals positions in Q3 2014 and 65 closed out, a net change of -5 holders.
- The largest Teva Pharmaceuticals buyer in Q3 2014 was Waddell & Reed Financial, an estimated $376M added.
- The largest Teva Pharmaceuticals seller in Q3 2014 was Norges Bank, an estimated $500M sold.
Based on aggregated 13F filings for Q3 2014.